甲氨蝶呤单药治疗抗TNF-α失败后克罗恩病的有效性与安全性:ENEIDA登记研究
基于西班牙ENEIDA登记的多中心回顾性研究,纳入110例抗TNF-α失败后开始甲氨蝶呤单药治疗的活动中度克罗恩病患者。12-16周短期临床应答率和缓解率分别为60%和30.9%;继续治疗者12个月和24个月长期有效率为82%和74%;44%出现不良事件,30.4%因此停药。
要点
- 抗TNF-α失败后甲氨蝶呤单药短期应答率60%、缓解率30.9%
- 第16周后继续治疗者12/24个月长期有效率82%/74%
- 短期未缓解与长期失败相关(HR 2.58),44%出现不良事件
核心结论
- 甲氨蝶呤单药可能是抗TNF-α失败后克罗恩病的有效选择。
研究设计与样本
- 西班牙ENEIDA登记的多中心回顾性观察性研究,纳入110例活动性克罗恩病且既往抗TNF-α失败后开始甲氨蝶呤单药治疗的患者。
主要发现
- 110例中既往失败1种抗TNF-α者占39%,失败2种者占55.6%。
- 12-16周短期临床应答率为60%,临床缓解率为30.9%。
- 第16周后继续治疗的74例中,12个月和24个月长期有效率分别为82%和74%。
- 多变量分析显示短期未缓解(对比缓解)与长期失败相关(HR 2.58,95%CI 1.95-3.68,P=0.028)。
- 100例评估不良事件,44%记录到不良事件,其中30.4%导致甲氨蝶呤停药。
关键数值与推荐
- 短期临床缓解定义为Harvey-Bradshaw指数(HBI)≤3分。
- 短期临床应答定义为HBI较基线下降≥3分。
- 长期有效性定义为从12-16周至最大随访期间无激素维持甲氨蝶呤治疗。
临床怎么用
- 对既往抗TNF-α失败的活动性克罗恩病患者,可考虑甲氨蝶呤单药作为治疗选项。
- 短期未达到临床缓解者长期失败风险较高,需密切监测并考虑调整治疗。
- 治疗中需警惕不良事件,约三成不良事件导致停药。
局限性
- 回顾性观察性研究设计。
- 样本量有限(110例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Methotrexate can be used to maintain remission in Crohn's disease patients who are intolerant to thiopurines. Data on its use as monotherapy in other scenarios are limited. AIM: To assess the effectiveness of methotrexate monotherapy in Crohn's disease patients after previous failure to anti-tumour necrosis factor (anti-TNFα) drugs. METHODS: A retrospective, observational multicentre study of data from the Spanish ENEIDA registry. Participants were patients with active Crohn's disease and previous failure to anti-TNFα started on methotrexate monotherapy. Short-term effectiveness was assessed at 12-16 weeks based on Harvey-Bradshaw index (HBI): clinical remission as HBI ≤ 3 points and clinical response as HBI drop of ≥ 3 points over baseline. Long-term effectiveness was defined as steroid-free methotrexate persistence from 12 to 16 weeks until maximum follow up. Adverse events were recorded. RESULTS: Data were compiled for 110 patients treated with methotrexate after a failed response to one (39%) or two (55.6%) anti-TNFα agents. Short-term clinical response and remission rates were 60% and 30.9% respectively. Of 74 patients who continued after week 16, long-term effectiveness was achieved in 82% and 74% at 12 and 24 months respectively. In the multivariate analysis, non-remission at short term (vs remission) was associated with long-term failure (HR 2.58, 95%CI 1.95-3.68, P = 0.028). Adverse events (evaluated in 100 patients) were recorded in 44%, and in 30.4% of these patients, they led to methotrexate discontinuation. CONCLUSIONS: The benefits observed suggest methotrexate monotherapy could be a valid option in Crohn's disease patients with previous failure to anti-TNFα.
引用
- Mesonero F, Castro-Poceiro J, Benítez JM, et al. Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-α: results from the ENEIDA registry. Aliment Pharmacol Ther. 2021. PMID: 33715177. doi:10.1111/apt.16315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。